Enterprise Value
-12.62M
Cash
128.6M
Avg Qtr Burn
N/A
Short % of Float
1.21%
Insider Ownership
19.18%
Institutional Own.
38.97%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ultevursen (QR-421a) (Exon 13) Details Mediated retinitis pigmentosa, Usher syndrome, Heart disease, Heart failure | Failed Discontinued | |
Sepofarsen (QR-110) (CEP290 gene) Details Leber congenital amaurosis, Eye disease , Genetic disorder | Failed Discontinued | |
QR-504a Details Genetic disorder, Eye disease , Leber congenital amaurosis | Failed Discontinued | |
QR-1123 (RNase H mediated cleavage) Details Mediated retinitis pigmentosa, Rho mediated retinitis pigmentosa | Failed Discontinued |